Thus, it is anticipated that strategies at disrupting the GLI-SOX2 signaling axis may be effective in sensitizing pancreatic cancer cells to gemcitabine-based therapy, the first line treatment for pancreatic cancer patients. This evidence concerns the gene SOX2 and pancreatic neoplasm.